Abstract Library

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2284 The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia

Introduction: There is previous data demonstrating that elevated gastrin levels could exert some effect potentiating the glucose-induced insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mavroeidi V

Authors: Moschouris P, Mavroeidi V, Nikolopoulos G, Tsoli M, Karapanagioti A,

Keywords: Gastric Neuroendocrine Tumors Type 1, ECL-Cells Hyperplasia, gastrin, glucose,

#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)

Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Shah R, Banks J, Smith J, Jacobs B,

Keywords: above-label somatostatin analogues, neuroendocrine tumor,

#2027 Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)

Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Megapanou M, Papantoniou D, Hayes A, von Stempel C,

Keywords: lanreotide, neuroendocrine tumor,